Breaking News Instant updates and real-time market news.

MYOK

MyoKardia

$41.87

-6.88 (-14.11%)

, SNY

Sanofi

$42.88

-0.54 (-1.24%)

07:09
01/03/19
01/03
07:09
01/03/19
07:09

Citi calls MyoKardia 'more interesting long term play' after Sanofi news

Citi analyst Mohit Bansal says that while some might see Sanofi (SNY) giving back all rights back to MyoKardia (MYOK) as a negative, he sees "significant strategic implications in longer term." The move gives MyoKardia more freedom to employ its "Divide and Conquer" precision strategy, Bansal tells investors in a research note titled "Full control makes MYOK an interesting long term play." The analyst also points out that Sanofi's decision was related to wanting U.S. control over Mavacamten, and is not related to the profile of the products. Bansal lowered his price target for MyoKardia to $70 from $90 and keeps a Buy rating on the shares.

MYOK

MyoKardia

$41.87

-6.88 (-14.11%)

SNY

Sanofi

$42.88

-0.54 (-1.24%)

  • 17

    Jan

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

MYOK MyoKardia
$41.87

-6.88 (-14.11%)

10/01/18
CANT
10/01/18
INITIATION
Target $90
CANT
Overweight
MyoKardia initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started MyoKardia with an Overweight rating and $90 price target.
09/28/18
SBSH
09/28/18
INITIATION
Target $90
SBSH
Buy
MyoKardia initiated with a Buy at Citi
Citi analyst Mohit Bansal started MyoKardia with a Buy rating and $90 price target. Early data for the company's lead program Mavacamten in hypertrophic cardiomyopathy indicated significant improvement in obstruction and function, Bansal tells investors in a research note. His analysis and physician checks make him confident around questions of long term safety and efficacy.
09/10/18
MSCO
09/10/18
INITIATION
Target $72
MSCO
Overweight
MyoKardia initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung initiated MyoKardia (MYOK) at Overweight with a $72 price target, stating that the obstructive hypertrophic cardiomyopathy Phase 2 data for its lead program, mavacamten, were "robust" and the fact that the company is partnered with Sanofi (SNY) gives him incremental confidence. He expects a mavacamten launch in oHCM in early 2022 and peak U.S. sales for the drug of greater than $1.3B.
08/09/18
WEDB
08/09/18
NO CHANGE
Target $77
WEDB
Outperform
MyoKardia price target raised to $77 from $64 at Wedbush
Wedbush analyst David Nierengarten raised his price target for MyoKardia (MYOK) to $77 from $64 as he now begins to value royalties on potential sales of mavacamten and MYK-491 in Europe based on increasing confidence that Sanofi (SNY) will elect to commercialize there. The analyst is also positive on MyoKardia ahead of the Phase 1b MYK-491 readout in dilated cardiomyopathy later this year, where a favorable safety profile and demonstration of clinical proof of mechanism could add at least $5/share to current levels. He reiterates an Outperform rating on MyoKardia shares.
SNY Sanofi
$42.88

-0.54 (-1.24%)

12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
12/11/18
12/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Buy from Neutral at Citi with analyst Michael Rollins saying he expects AT&T to further benefit from the "measured" promotional environment in wireless, while improving its competitive position from FirstNet and the marketing of its network enhancements, branded 5G Evolution. 2. Sanofi (SNY) upgraded to Buy from Hold at Jefferies with analyst Peter Welford saying he believes European large-cap pharmaceuticals are entering a period of sustained earnings momentum which should justify valuations above the historic average for the sector. 3. Total (TOT) upgraded to Buy from Neutral at BofA/Merrill. 4. Zynga (ZNGA) upgraded to Outperform from Neutral at Macquarie. 5. Allstate (ALL) upgraded to Hold from Sell at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/11/18
JEFF
12/11/18
UPGRADE
JEFF
Buy
Sanofi upgraded to Buy from Hold at Jefferies
Jefferies analyst Peter Welford upgraded Sanofi to Buy and raised his price target for the shares to EUR 90 from EUR 75. The analyst believes European large-cap pharmaceuticals are entering a period of sustained earnings momentum which should justify valuations above the historic average for the sector.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Powell on changing policy: »

Powell on changing…

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

BA

Boeing

$362.00

-0.42 (-0.12%)

11:14
11/14/19
11/14
11:14
11/14/19
11:14
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing moves to session…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
3-Month Bill Announcement Offering Amount data reported »

3-Month Bill Announcement…

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
10-Yr TIPS Announcement CUSIP Number data reported »

10-Yr TIPS Announcement…

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
10-Yr TIPS Announcement Offering Amount data reported »

10-Yr TIPS Announcement…

11:10
11/14/19
11/14
11:10
11/14/19
11:10
General news
6-Month Bill Announcement Offering Amount data reported »

6-Month Bill Announcement…

BMRN

BioMarin

$75.55

-0.54 (-0.71%)

11:07
11/14/19
11/14
11:07
11/14/19
11:07
Hot Stocks
BioMarin sees GAAP break-even or better in 2020 assuming Valoctocogene launch »

BioMarin Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

GILD

Gilead

$62.48

-0.85 (-1.34%)

11:05
11/14/19
11/14
11:05
11/14/19
11:05
Options
Gilead call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

11:05
11/14/19
11/14
11:05
11/14/19
11:05
General news
Powell:the day of reckoning could be "quite far off," »

Powell:the day of…

USO

United States Oil Fund

$12.05

0.09 (0.75%)

11:00
11/14/19
11/14
11:00
11/14/19
11:00
General news
Crude inventories for week of November 8 »

Crude oil inventories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$263.91

-0.61 (-0.23%)

10:58
11/14/19
11/14
10:58
11/14/19
10:58
On The Fly
Maxim says sell Apple on concern about 2020 iPhone sales »

Maxim analyst Nehal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

$237.81

0.17 (0.07%)

10:56
11/14/19
11/14
10:56
11/14/19
10:56
Periodicals
Breaking Periodicals news story on Air Products »

Lombard Odier's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
11/14/19
11/14
10:55
11/14/19
10:55
General news
Powell: the U.S. is the star economy »

Powell: the U.S. is the…

OPTT

Ocean Power

$1.49

-0.005 (-0.33%)

10:55
11/14/19
11/14
10:55
11/14/19
10:55
Conference/Events
Ocean Power to host business news update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

AAPL

Apple

$263.82

-0.7 (-0.26%)

, UBER

Uber

$25.97

-0.73 (-2.73%)

10:53
11/14/19
11/14
10:53
11/14/19
10:53
On The Fly
Apple downgrade, Uber upgrade among today's top analyst calls »

Check out today's top…

AAPL

Apple

$263.82

-0.7 (-0.26%)

UBER

Uber

$25.97

-0.73 (-2.73%)

KHC

Kraft Heinz

$31.79

-1.1 (-3.34%)

VZ

Verizon

$59.16

-0.25 (-0.42%)

T

AT&T

$38.93

-0.22 (-0.56%)

TMUS

T-Mobile

$77.04

-0.98 (-1.26%)

ATUS

Altice USA

$26.91

0.07 (0.26%)

BYND

Beyond Meat

$81.24

2.26 (2.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 29

    Jan

  • 30

    Jan

10:50
11/14/19
11/14
10:50
11/14/19
10:50
General news
More Powell: the long expansions have been a function of getting inflation under control »

More Powell: the long…

VTGN

VistaGen Therapeutics

$0.34

-0.7449 (-68.65%)

10:45
11/14/19
11/14
10:45
11/14/19
10:45
Downgrade
VistaGen Therapeutics rating change  »

William Blair downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$191.00

0.84 (0.44%)

10:45
11/14/19
11/14
10:45
11/14/19
10:45
Options
Cigna call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 22

    Nov

  • 09

    Dec

  • 06

    Feb

10:45
11/14/19
11/14
10:45
11/14/19
10:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY hit…

10:45
11/14/19
11/14
10:45
11/14/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

10:45
11/14/19
11/14
10:45
11/14/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
11/14/19
11/14
10:45
11/14/19
10:45
General news
Breaking General news story  »

Week of 11/8 EIA…

VTGN

VistaGen Therapeutics

$0.33

-0.7525 (-69.35%)

10:38
11/14/19
11/14
10:38
11/14/19
10:38
Downgrade
VistaGen Therapeutics rating change  »

VistaGen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.